|
市場調查報告書
新抗癌藥研發之目標導向策略
Target-Based Approaches for Discovering Novel Oncology Drugs
|
本報告已在2011年07月19日停止出版。
細胞毒性治療在現代的癌症治療中扮演著重要的角色。但是由於對既有的細胞毒性藥轉而有毒的擔心，經改良後副作用較少的新藥研發有其必要性。製藥企業對於新目標之鎖定工作投入相當多的資源與努力。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. （總公司：麻薩諸塞州），針對新抗癌藥研發之目標導向策略進行調查分析，經系統整理後出版報告書 "Target-Based Approaches for Discovering Novel Oncology Drugs" 。
本報告書內容包括：新抗癌藥瀏覽、目標設定下研發中藥品的相關動向等。共計 17 頁的內容綱要摘記如下：。
序章
人類表皮生長因子接受體
Bcr ／ abl 激酶
蛋白質酶體（ Proteasome ）
自然凋亡細胞路徑
細胞繁殖與生存
蛋白去乙酰化酶（ HDAC ）
血管形成目標
目標策略今後的展望
Abstract
In This Issue...
Despite recent improvements in treatment, cancer remains a huge public health
burden. Cytotoxic treatments play a critical role in modern cancer therapy.
Unfortunately, traditional cytotoxic agents are associated with significant
toxicity. In an effort to discover new oncology drugs with improved clinical
benefits and fewer side effects, drug developers have committed substantial
resources to identifying novel cancer targets and compounds that interact with
those targets. These efforts have been facilitated by a plethora of
technologies developed in recent years to generate and exploit genomic and
proteomic information. In this report, we review novel cancer drug targets and
the drugs under development directed at these targets.
Table of Contents
Introduction
Human Epidermal Growth Factor Receptors
Bcr/abl Kinase
The Proteasome
Apoptosis Pathways
Cellular Proliferation and Survival
Histone Deacetylase
Angiogenesis Targets
Outlook for Target-Based Approaches
|
